These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12839846)

  • 41. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer.
    Lovrics PJ; Chen V; Coates G; Cornacchi SD; Goldsmith CH; Law C; Levine MN; Sanders K; Tandan VR
    Ann Surg Oncol; 2004 Sep; 11(9):846-53. PubMed ID: 15313737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
    Cermik TF; Mavi A; Basu S; Alavi A
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
    Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
    AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients.
    Yang JH; Nam SJ; Lee TS; Lee HK; Jung SH; Kim BT
    Jpn J Clin Oncol; 2001 Jan; 31(1):1-6. PubMed ID: 11256834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
    World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repeat sentinel lymph node biopsy in patients with ipsilateral recurrent breast cancer after breast-conserving therapy and negative sentinel lymph node biopsy: a prospective study.
    Folli S; Falco G; Mingozzi M; Buggi F; Curcio A; Ferrari G; Taffurelli M; Regolo L; Nanni O
    Minerva Chir; 2016 Apr; 71(2):73-9. PubMed ID: 26207566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDG-PET/CT in the staging of local/regional metastases in breast cancer.
    Robertson IJ; Hand F; Kell MR
    Breast; 2011 Dec; 20(6):491-4. PubMed ID: 21807517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
    J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of Axillary SUV
    Karabacak U; Turkan H; Coskun G; Mollaoglu MC; Hasbek Z; Karadayi K
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):374-379. PubMed ID: 37190706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose High-resolution
    Ferdová E; Baxa J; Ňaršanská A; Hes O; Fínek J; Topolčan O; Ferda J
    Anticancer Res; 2018 Jul; 38(7):4145-4148. PubMed ID: 29970542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.